| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.91.1.23 |
| P698 | PubMed publication ID | 7805207 |
| P2093 | author name string | T Palosuo | |
| L Tenkanen | |||
| V Manninen | |||
| K Aho | |||
| O Vaarala | |||
| M Mänttäri | |||
| M Puurunen | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 23-27 | |
| P577 | publication date | 1995-01-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | |
| P478 | volume | 91 |
| Q46171431 | 25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies |
| Q35627251 | A rare presentation of primary antiphospholipid syndrome |
| Q37658524 | Accelerated atherosclerosis in SLE: mechanisms and prevention approaches |
| Q26820245 | Accelerated atherosclerosis in patients with SLE--mechanisms and management |
| Q60678824 | Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies |
| Q33573479 | Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms |
| Q79899539 | Anti-ox-LDL and anticardiolipin autoantibodies in patients after cardiac transplantation |
| Q42209290 | Antiphosphatidyl serine autoantibodies and premature coronary events. |
| Q43626449 | Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. |
| Q35647424 | Antiphospholipid antibodies and stroke |
| Q73086663 | Antiphospholipid antibodies and the antiphospholipid antibody syndrome |
| Q37358421 | Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein |
| Q46165765 | Antiphospholipid antibodies from a patient with primary antiphospholipid syndrome enhance experimental atherosclerosis |
| Q83162687 | Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort |
| Q33825446 | Antiphospholipid antibodies predict progression of abdominal aortic aneurysms |
| Q36832522 | Antiphospholipid antibody effects on monocytes |
| Q34271982 | Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis |
| Q83177928 | Arterial compliance: is it reduced in antiphospholipid syndrome? |
| Q73251576 | Association between anticardiolipin antibodies and mortality in patients with peripheral arterial disease |
| Q37228076 | Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study |
| Q54117179 | Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina. |
| Q28345191 | Atherosclerosis |
| Q35148621 | Atherosclerosis and antiphospholipid syndrome |
| Q37319989 | Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings |
| Q35525108 | Atherosclerosis in systemic lupus erythematosus |
| Q84430476 | Atherosclerosis risk factors in systemic lupus erythematosus |
| Q38365624 | Atherosclerotic vascular disease in the autoimmune rheumatologic patient |
| Q37824302 | Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases |
| Q74190882 | Autoimmune and inflammatory responses may have an additive effect in postpercutaneous transluminal coronary angioplasty restenosis |
| Q74211615 | Beta2-glycoprotein I-dependent and -independent anticardiolipin antibody in non-obese diabetic (NOD) mice |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q36355415 | Cardiac manifestations of rheumatological conditions: a narrative review |
| Q37425906 | Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q87355706 | Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C |
| Q51559659 | Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients. |
| Q73289480 | Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain |
| Q40841563 | Current insights into the "antiphospholipid" syndrome: clinical, immunological, and molecular aspects |
| Q37853050 | Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome |
| Q58421151 | Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment |
| Q77769404 | Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease |
| Q28165262 | Evidence-based management of thrombosis in the antiphospholipid antibody syndrome |
| Q33753448 | F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo |
| Q74456594 | Hughes (antiphospholipid) syndrome. Clinical features |
| Q34006304 | Immunological responses to oxidized LDL. |
| Q26750752 | Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis |
| Q35549285 | Inflammation-mediated rheumatic diseases and atherosclerosis |
| Q61943926 | LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES |
| Q35099172 | Laboratory diagnosis of the antiphospholipid syndrome |
| Q84329906 | Life-threatening cardiac manifestations of primary antiphospholipid syndrome |
| Q73342706 | Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty |
| Q36577423 | Mechanisms of disease: atherosclerosis in autoimmune diseases |
| Q51821388 | Pathogenesis and management of antiphospholipid syndrome. |
| Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
| Q34674429 | Primary anti-phospholipid antibody syndrome (APS): current concepts |
| Q34354761 | Prognosis in antiphospholipid syndrome |
| Q35113270 | Prothrombotic determinants of coronary atherothrombosis |
| Q73085936 | Recurrent acute coronary events in a patient with primary antiphospholipid syndrome: successful management with intracoronary stenting |
| Q44491239 | Relation of preexisting anti-beta2GPI antibodies to infarct size in a rat model |
| Q74269420 | Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men |
| Q34173872 | Risk factors for development of left ventricular thrombus after first acute anterior myocardial infarction-association with anticardiolipin antibodies |
| Q36644837 | Risk factors in cardiovascular disease in systemic lupus erythematosus |
| Q93092136 | Risk of Thrombosis in Patients Presenting with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA) |
| Q44760247 | Specific cardiomyopathy in lupus patients: report of three cases |
| Q43419630 | Systemic lupus erythematosus and cardiovascular disease |
| Q37033345 | Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention |
| Q37589607 | The clinical significance of anticardiolipin antibody levels in patients with acute myocardial infarction: a regional study |
| Q37876166 | The prediction of coronary atherosclerosis employing artificial neural networks |
| Q35683321 | The role of endothelial cell reactive antibodies in peripheral vascular disease |
| Q28188901 | Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease |
| Q55547645 | Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. |
| Q53643980 | Thrombophilic state in young patients with acute myocardial infarction. |
| Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
| Q84600032 | [Antiphospholipid syndrome treatment, to whom, when and how long?] |
| Q73672348 | [Aspirin and antiphospholipid syndrome] |
| Q81575733 | [Cardiovascular monitoring of patients with systemic lupus erythematosus] |
Search more.